Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 10, 2017, Pages 1521-1530.e8

  Kim, Rebecca G ^a   Loomba, Rohit ^a   Prokop, Larry J ^b   Singh, Siddharth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cholesterol lowering Drug; Cirrhosis; Liver Fibrosis; Meta analysis; RCT

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ALCOHOL LIVER DISEASE; BLEEDING; CHRONIC LIVER DISEASE; COMPENSATED LIVER CIRRHOSIS; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; MORTALITY; PORTAL HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VARICEAL BLEEDING; VARICOSIS; ALCOHOLISM; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; FIBROSIS; LIVER FAILURE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ALCOHOLISM; FIBROSIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER FAILURE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85030674172     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.04.039     Document Type: Review

References (57)

1. Xu, J., Murphy, S.L., Kochanek, K.D., et al. Deaths: final data for 2013. National Vital Statistics Reports 64 (2016), 1–119.
2. Grundy, S.M., HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319 (1988), 24–33.
3. Endo, A., Tanzawa, K., Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72 (1976), 323–326.
4. Tsujita, Y., Kuroda, M., Tanzawa, K., et al. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32 (1979), 307–313.
5. Shigematsu, H., Hata, Y., Yamamoto, M., et al. Treatment of hypercholesterolemia with a HMG CoA reductase inhibitor (CS-500). I. Phase I study in normal subjects. Geriatr Med 17 (1979), 1564–1570.
6. Yamamoto, A., Sudo, H., Endo, A., Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 35 (1980), 259–266.
7. Mabuchi, H., Haba, T., Tatami, R., et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 305 (1981), 478–482.
8. Tobert, J.A., Bell, G.D., Birtwell, J., et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in healthy volunteers. J Clin Invest 69 (1982), 913–919.
9. The Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicenter study. JAMA 256 (1986), 2829–2834.
10. Havel, R.J., Hunninghake, D.B., Illingworth, D.R., et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med 107 (1987), 609–615.
11. Musial, J., Undas, A., Gajewski, P., et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77 (2001), 247–253.
12. Ridker, P.M., Rifai, N., Lowenthal, S.P., Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001), 1191–1193.
13. Albert, M.A., Staggers, J., Chew, P., et al. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 141 (2001), 893–898.
14. Lefer, D.J., Statins as potent antiinflammatory drugs. Circulation 106 (2002), 2041–2042.
15. McGirt, M.J., Lynch, J.R., Parra, A., et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 33 (2002), 2950–2956.
16. Kalinowski, L., Dobrucki, L.W., Brovkovych, V., et al. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105 (2002), 933–938.
17. Laufs, U., Fata, V.L., Plutzky, J., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998), 1129–1135.
18. Laufs, U., Fata, V.L., Liao, J.K., Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272 (1997), 31725–31729.
19. Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998), 2711–2719.
20. Llevadot, J., Murasawa, S., Kureishi, Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001), 399–405.
21. Anderson, T.J., Meredith, I.T., Yeung, A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 (1995), 488–493.
22. Treasure, C.B., Klein, J.L., Weintraub, W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995), 481–487.
23. O'Driscoll, G., Green, D., Taylor, R.R., Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997), 1126–1131.
24. Zafra, C., Abraldes, J.G., Turnes, J., et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126 (2004), 749–755.
25. Abraldes, J.G., Rodriguez-Vilarrupla, A., Graupera, M., et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 46 (2007), 1040–1046.
26. Moreno, M., Ramalho, L.N., Sancho-Bru, P., et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 296 (2009), G147–G156.
27. Trebicka, J., Hennenberg, M., Odenthal, M., et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53 (2010), 702–712.
28. Mura, V.L., Pasarin, M., Meireles, C.Z., et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 57 (2013), 1172–1181.
29. Marrone, G., Maeso-Diaz, R., Garcia-Cardena, G., et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 64 (2015), 1434–1443.
30. Singh, S., Singh, P.P., Singh, A.G., et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144 (2013), 323–332.
31. Tsan, Y., Lee, C., Wang, J., et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Value Health 15 (2012), A602–A603.
32. El-Serag, H.B., Johnson, M.L., Hachem, C., et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136 (2009), 1601–1608.
33. Abraldes, J.G., Albillos, A., Banares, R., et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136 (2009), 1651–1658.
34. Abraldes, J.G., Villanueva, C., Aracil, C., et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150 (2016), 1160–1170.
35. Huang, Y.-W., Lee, C.-L., Yang, S.-S., et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol 111 (2016), 976–985.
36. Kumar, S., Grace, N.D., Qamar, A.A., Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci 59 (2014), 1958–1965.
37. Mohanty, A., Tate, J.P., Garcia-Tsao, G., Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150 (2016), 430–440.
38. Pollo-Flores, P., Soldan, M., Santos, U.C., et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 47 (2015), 957–963.
39. Simon, T.G., Bonilla, H., Yan, P., et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 64 (2016), 47–57.
40. Simon, T.G., King, L.Y., Zheng, H., et al. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 62 (2015), 18–23.
41. Yang, Y.-H., Chen, W.-C., Tsan, Y.-T., et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 63 (2015), 1111–1117.
42. Hsiang, J.C., Wong, G.L.-H., Tse, Y.-K., et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis. J Hepatol 63 (2015), 1190–1197.
43. Oliver, N.T., Hartman, C.M., Kramer, J.R., et al. Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals. AIDS 30 (2016), 2469–2476.
44. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100.
45. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: Higgins JPT, Green S, eds. The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org. Accessed November 1, 2016.
46. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed November 1, 2016.
47. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
48. Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
49. Guyatt, G., Oxman, A.D., Sultan, S., et al., GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66 (2013), 151–157.
50. Chang, F.M., Wang, Y.P., Lang, H.C., et al. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study. Hepatology, 2017 http://dx.doi.org/10.1002/hep.29172.
51. Bang, U.C.B., Bendtsen, F., The impact of statins on mortality in patients with compensated or decompensated alcoholic cirrhosis in a nationwide retrospective study. Hepatology 54 (2016), 131A–132A.
52. Butt, A.A., Yan, P., Bonilla, H., et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 62 (2015), 365–374.
53. Dongiovanni, P., Petta, S., Mannisto, V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 63 (2015), 705–712.
54. Gupta, T.K., Toruner, M., Chung, M.K., et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 (1998), 926–931.
55. Rockey, D.C., Chung, J.J., Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114 (1998), 344–351.
56. Shah, V., Toruner, M., Haddad, F., et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 117 (1999), 1222–1228.
57. Targownik, L.E., Suissa, S., Understanding and avoiding immortal-time bias in gastrointestinal observational research. Am J Gastroenterol 110 (2015), 1647–1650.